You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康方生物-B(09926.HK):AK111治療中重度斑塊型銀屑病II期臨牀研究完成受試者入組
格隆匯 09-29 06:22

格隆匯9月29日丨康方生物-B(09926.HK)發佈公吿,公司自主研發的IL-17A單克隆抗體(研發代號:AK111)治療中度至重度斑塊型銀屑病的II期臨牀研究已完成受試者入組。公司預期於2022年初啟動III期臨牀研究。

此前,AK111已完成中度至重度斑塊型銀屑病受試者多次重複給藥的Ib期臨牀研究。臨牀數據結果顯示,在給藥頻次低於同靶點藥物的情況下,接受各劑量組AK111治療的受試者在12周的病情有明顯改善,達到銀屑病面積與嚴重性指數(“PASI”)評分,包括PASI90、PASI100及醫生整體評估(PGA)達到清潔(0)或幾乎清潔(1)的高應答率,且停藥後12周可維持長期療效。同時,AK111在銀屑病受試者中顯示了良好的安全性和耐受性。

銀屑病是一種慢性免疫介導的皮膚疾病,全球患病人數約為1.25億。自IL-17新靶點開啟治療自身免疫疾病,尤其是銀屑病治療的新時代,公司迅速佈局在銀屑病及強直性脊柱炎治療領域的臨牀研究,體現了公司在創新醫藥領域的研發實力和創新能力,顯示了公司在生物科技創新領域趨勢的引領地位。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account